[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gain Therapeutics Inc (GANX)

Gain Therapeutics Inc (GANX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 74,644
  • Shares Outstanding, K 42,654
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,160 K
  • EBIT $ -20 M
  • EBITDA $ -20 M
  • 60-Month Beta 0.15
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.54

Options Overview Details

View History
  • Implied Volatility 215.48% (+32.46%)
  • Historical Volatility 66.48%
  • IV Percentile 66%
  • IV Rank 23.30%
  • IV High 810.99% on 12/10/25
  • IV Low 34.58% on 09/04/25
  • Expected Move (DTE 26) 0.0000 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 82
  • Volume Avg (30-Day) 262
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 5,806
  • Open Int (30-Day) 5,218
  • Expected Range 1.7500 to 1.7500

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.14
  • Number of Estimates 3
  • High Estimate $-0.13
  • Low Estimate $-0.16
  • Prior Year $-0.19
  • Growth Rate Est. (year over year) +26.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5900 +10.06%
on 07/15/26
2.2400 -21.88%
on 06/30/26
+0.0100 (+0.57%)
since 06/24/26
3-Month
1.5300 +14.38%
on 05/19/26
2.2400 -21.88%
on 06/30/26
-0.2200 (-11.17%)
since 04/24/26
52-Week
1.4100 +24.11%
on 08/01/25
4.3400 -59.68%
on 12/11/25
+0.0700 (+4.17%)
since 07/24/25

Most Recent Stories

More News
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update

BETHESDA, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development...

GANX : 1.7500 (-3.85%)
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease

IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26 FDA’s decision follows positive Phase 1 results for GT-02287 in both healthy...

GANX : 1.7500 (-3.85%)
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

BETHESDA, Md., June 10, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development...

GANX : 1.7500 (-3.85%)
Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026

MDS-UPDRS scores remained stable and durable across overall study population after 150 days of treatment with GT-02287 Differential response between participants with low and high baseline GluSph...

GANX : 1.7500 (-3.85%)
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update

BETHESDA, Md., May 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development...

GANX : 1.7500 (-3.85%)
Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026

BETHESDA, Md., April 24, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development...

GANX : 1.7500 (-3.85%)
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update

BETHESDA, Md., March 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development...

GANX : 1.7500 (-3.85%)
Gain Therapeutics to Present at the 38th Annual ROTH Conference

BETHESDA, Md., March 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development...

GANX : 1.7500 (-3.85%)
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026

Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with a reduction following 90 days of dosing with GT-02287 in individuals with...

GANX : 1.7500 (-3.85%)
Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update

Interim analysis of Phase 1b clinical study of GT-02287, including biomarker and clinical endpoints, will be presented in oral symposium Company remains on track to initiate Phase 2 clinical trial...

GANX : 1.7500 (-3.85%)

Business Summary

Gain Therapeutics Inc. is redefining drug discovery with its See-Tx(TM) target identification platform. It involved in identifying and optimizing allosteric binding sites which have never before been targeted. The company is unlocking new treatment options for difficult-to-treat disorders characterized...

See More

Key Turning Points

3rd Resistance Point 1.8635
2nd Resistance Point 1.8367
1st Resistance Point 1.7934
Last Price 1.7500
1st Support Level 1.7233
2nd Support Level 1.6965
3rd Support Level 1.6532

See More

52-Week High 4.3400
Fibonacci 61.8% 3.2207
Fibonacci 50% 2.8750
Fibonacci 38.2% 2.5293
Last Price 1.7500
52-Week Low 1.4100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.